Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ... [Yahoo! Finance]
Abeona Therapeutics Inc. (ABEO)
Last abeona therapeutics inc. earnings: 3/16 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.abeonatherapeutics.com
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Release Date: March 17, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Abeona Therapeutics Inc ( NASDAQ:ABEO ) has seen growing patient demand for Zivasskin, the first and only autologous cell-based gene therapy for RDE. The company has successfully treated its first commercial patient and is ramping up its launch execution in 2026. All major commercial payers, including UnitedHealthcare, Cigna, Aetna, Anthem, and most Blue Cross Blue Shield plans, have published coverage policies for Zivasskin. Abeona Therapeutics Inc ( NASDAQ:ABEO ) has a permanent HCPCS J code for Zivasskin, effective January 1, 2026, which will streamline billing and reimbursement. The company recorded a $152.4 million gain from the sale of its rare pediatric disease priority review voucher, contributing to a net income of $71.2 million for 2025. Negative Points The launch of Ziva
Show less
Read more
Impact Snapshot
Event Time:
ABEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABEO alerts
High impacting Abeona Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ABEO
News
- Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB [Seeking Alpha]Seeking Alpha
- Abeona Therapeutics (ABEO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point [Seeking Alpha]Seeking Alpha
- Abeona Therapeutics (ABEO) was given a new $17.00 price target by Stifel Nicolaus.MarketBeat
- Abeona (ABEO) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
ABEO
Earnings
- 3/17/26 - Beat
ABEO
Sec Filings
- 3/20/26 - Form 8-K
- 3/17/26 - Form 10-K
- 3/17/26 - Form 8-K
- ABEO's page on the SEC website